Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Do not call
En
Ipca Laboratories Ltd. Share Price
Day's Range
Low
₹1,931.20
High
₹1,956.00
Price Summary
| Previous Close | ₹1,939.40 |
|---|---|
| Day's Range | ₹1,931.20 - ₹1,956.00 |
| Open | ₹1,947.50 |
| 52 Week Range | ₹1,293.90 - ₹2,038.00 |
| Volume | 10,843 |
| Market Cap | ₹0.05 |
| Previous Close | ₹1,926.00 |
|---|---|
| Day's Range | ₹1,926.00 - ₹1,943.95 |
| Open | ₹1,941.40 |
| 52 Week Range | ₹1,295.00 - ₹2,039.30 |
| Volume | 1,004 |
| Market Cap | ₹0.05 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 210.29 |
|---|---|
| Market Cap (₹ in Mn) | 0.05 |
| Dividend Yield(%) | 0.31 |
| Price/Earning (TTM) | 35.07 |
| TTM EPS (₹) | 55.28 |
| P/E Ratio | 35.64 |
| Book Value(₹) | 5.67 |
| PAT Margin (%) | 12.35 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 19.41 |
| Trade Value ( ₹ in Lacs) | 19.34 |
|---|---|
| Market Cap (₹ in Mn) | 0.05 |
| Dividend Yield(%) | 0.31 |
| Price/Earning (TTM) | 35.07 |
| TTM EPS (₹) | 55.28 |
| P/E Ratio | 35.64 |
| Book Value(₹) | 5.67 |
| PAT Margin (%) | 12.35 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 19.41 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 19303.2 | 89395.9 |
| Expenses | N/A | N/A |
| PBT | 4083.1 | 11288.5 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 3047.4 | 7852.4 |
About Ipca Laboratories Ltd.
| Founded | 1949 |
|---|---|
| Managing Director | Pranay Godha |
| NSE Symbol | IPCALAB |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,54,913.91 | 1,882.55 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 3,00,380.35 | 11,324.50 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,81,169.21 | 4,735.85 | 3,672.30 - 3,672.30 |
| Laurus Labs Ltd. | 1,31,566.03 | 2,409.75 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,25,837.35 | 733.45 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,23,511.02 | 8,508.00 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,18,712.93 | 1,198.90 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,14,933.37 | 1,382.70 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,14,477.74 | 1,411.50 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,09,746.08 | 2,645.80 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Ipca Laboratories informs about board meeting
Ipca Laboratories informs about analyst meet outcome
Aurobindo Pharma informs about unaudited financial results
Gujarat Kidney & Superspeciality informs about transcript of earnings call
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Gujarat Kidney & Superspeciality has informed that it enclosed the transcript of the Earnings call with Analysts / Investors held on Thursday, November 05, 2026, post declaration of the Financial Results for the quarter and half year ended September 30, 2026. The same has also been disseminated on the website of the Company.
The above information is a part of company’s filings submitted to BSE.
Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Unit-II, an API manufacturing facility of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Gaddapotharam, Industrial Development Area - Kazipally Industrial Area, Jinnaram Mandal, Sangareddy District, 502319, Telangana from September 7th to September 15th, 2026. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is closed under 21 CFR 20.64(d)(3).
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Ipca Laboratories Ltd. is ₹1,939.40 as of 2026-11-12.
The market capitalisation of Ipca Laboratories Ltd. is ₹49,178.03 as of 2026-11-11.
The 1-year return of Ipca Laboratories Ltd. is 617.40% as of 2026-11-12.
The P/E ratio of Ipca Laboratories Ltd. is 35.64 as of 2026-11-12.
The 52-week high and low of Ipca Laboratories Ltd. are ₹2,038.00 and ₹1,293.90, respectively, as of 2026-11-12.
People Also Ask
Ipca Laboratories Ltd. manufactures a vast array of active pharmaceutical ingredients (APIs) and finished drug formulations. The company holds dominant global market shares in producing anti-malarial, rheumatology, and cardiovascular medications, serving both domestic retail and heavy international export markets.
Ipca Laboratories Ltd. works with global entities by exporting heavily vertically integrated APIs and formulations to over 100 countries. It partners with domestic hospitals and clinics through a massive medical representative network that ensures widespread availability of its specialised generic drugs.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
